Scientists are making significant strides in the development of artificial blood, a breakthrough that may address ongoing blood shortages and enhance the safety of transfusions. Research conducted by the World Health Organization (WHO) indicates that millions worldwide suffer from a lack of access to blood, contributing to preventable deaths each year.
Blood plays a crucial role in the body, facilitating oxygen transport and the removal of waste. As scientists investigate this complex biology, laboratory-grown blood has shown promise, particularly in clinical trials involving patients with rare blood types. The potential of synthetic blood, engineered for rapid medical use, further underscores the urgency in this realm of research.
Artificial blood encompasses both lab-grown and synthetic varieties. The latter, still in experimental stages, is entirely man-made and devoid of human cells. Its design focuses on emergency scenarios where immediate blood type compatibility is often a challenge. The U.S. military, for example, has invested million into ErythroMer, a synthetic blood substitute aimed at achieving universal compatibility without refrigeration.
Meanwhile, lab-grown blood is derived from human red blood cells cultivated in a controlled laboratory environment. This innovative approach could revolutionize treatment in emergencies, enhancing the effectiveness of transfusions for trauma patients while ensuring safety. Cedric Ghevaert, a UK-based professor of transfusion medicine, points to the advantages of using lab-grown platelets in specific medical situations, such as trauma cases.
The process of creating lab-grown blood begins with stem cells, particularly haematopoietic stem cells, which have the capacity to generate various blood cells like red blood cells and platelets. By utilizing specific growth factors in a lab environment, scientists can induce these cells to mature into fully functional red blood cells. Moreover, advancements in gene editing techniques may allow for the production of blood lacking specific group markers, paving the way for greater compatibility.
As of now, lab-grown and synthetic blood products are still within the research and development phase. Recent clinical trials, including a notable one in the UK, marked the first successful transfusion of lab-grown red blood cells into human volunteers, highlighting the safety of these innovative treatments. While further trials will be essential for regulatory approval, the cost of production has considerably decreased from over ,000 in 2013 to less than ,000 today.
While there are promising developments, various hurdles remain before artificial blood can be produced commercially. Regulatory frameworks are challenging to navigate, as health authorities decide whether these products are classified as cell therapy or medicine. Addressing production scale and ensuring blood safety will remain paramount.
Importantly, synthetic blood offers the ability to cater to rarer blood types due to its cell-free nature, which circumvents the need for specific blood group markers. This approach not only simplifies transfusions but also alleviates the scarcity faced predominantly by patients with rare blood types, enhancing access to life-saving measures.
Experts believe that the advent of artificial blood could significantly mitigate blood shortages globally, particularly in lower- and middle-income countries. The WHO reports that 40% of blood donations are sourced from high-income nations, which represent only 16% of the global population. Significant disparities in blood availability contribute to higher mortality rates during crises in regions such as sub-Saharan Africa and South Asia.
With the ability to generate blood products swiftly during emergencies like pandemics or natural disasters, lab-grown blood could play a transformative role in global health security, reinforcing its potential as a crucial resource in the face of mounting medical demands.
#HealthNews #ScienceNews